Independent · non-commercial · publishes on a quarterly cycle|Current cycle 2026 Q3
Compound Evidence InstituteEvidence synthesis · established 2023Graded assessments of compounds, trials, methods and supply
Document set current to 30 July 2026
Bibliographic record

Lixisenatide in patients with type 2 diabetes and acute coronary syndrome

Pfeffer MA, Claggett B, Diaz R, Dickstein K, Gerstein HC, Køber LV, Lawson FC, Ping L, Wei X, Lewis EF, Maggioni AP, McMurray…. New England Journal of Medicine 2015

Document identifier
CEI-BR-084
Series
Bibliographic record
Version
1.0
Published
30 Jul 2026
Last reviewed
30 Jul 2026
Certainty
Not rated

§1Bibliographic record

§1.1Record

Authors
Pfeffer MA, Claggett B, Diaz R, Dickstein K, Gerstein HC, Køber LV, Lawson FC, Ping L, Wei X, Lewis EF, Maggioni AP, McMurray JJV, Probstfield JL, Riddle MC, Solomon SD, Tardif JC
Title
Lixisenatide in patients with type 2 diabetes and acute coronary syndrome
Source
New England Journal of Medicine
Year
2015
Volume, issue, pages
373(23):2247–2257
Digital object identifier
10.1056/NEJMoa1509225
PubMed identifier
26630143
Record type
Journal article
Institute identifier
CEI-BR-084

§1.2Institute documents citing this record

Table 1. Documents in the Institute set that cite this record.

§1.3Subject tags

lixisenatide cardiovascular ELIXA

Nothing published by the Institute is medical advice, a diagnosis, a prescription, a treatment recommendation or a purchasing recommendation. Compounds supplied for research use are not approved for human or veterinary use in any jurisdiction, and a favourable analytical assessment of a supplier is not a statement that any product is safe or effective. The Institute publishes certainty ratings and never recommendations. No telephone number, messaging handle or ordering channel appears anywhere on this site.